Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor
Authors
Keywords
CLR457, Pan-PI3K inhibitor, Therapeutic index, Phase I, Preclinical
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-03
DOI
10.1007/s10637-018-0627-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AKT Inhibition in Solid Tumors With AKT1 Mutations
- (2017) David M. Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
- (2016) William J. Scott et al. ChemMedChem
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- Signaling cross-talk in the resistance to HER family receptor targeted therapy
- (2013) H Yamaguchi et al. ONCOGENE
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- A new mathematical approach for the estimation of the AUC and its variability under different experimental designs in preclinical studies
- (2011) Carmen Navarro-Fontestad et al. PHARMACEUTICAL STATISTICS
- Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
- (2011) Matthew T. Burger et al. ACS Medicinal Chemistry Letters
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
- Critical aspects of the Bayesian approach to phase I cancer trials
- (2008) Beat Neuenschwander et al. STATISTICS IN MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search